PLA-Inhibitors (stoPLA): New class of NSAIDs for oral and transdermal pain treatment

Phospholipase A2 (PLA2) designates a large and diverse

group of enzymes that cleave phospholipids at the sn-2- position. This metabolic step is instrumental in a variety of pathogenic processes causing pain, fever and inflammation. Presently glucocortidoids are used for inhibition of PLA2. Unfortunately, glucocortidoids have serious side effects which limit their use as medication for pain treatment. stoPLA is a new class of heteroaryl-substituted acetone derivatives for the effective inhibition of PLA2, especially of cytosolic PLA2. These compounds effectively interact with the synthesis of prostaglandins and leukotrienes and reduce inflammatory processes. The new heteroarylsubstituted acetone derivatives have also an excellent solubility profile and are stable against metabolic inactivation through ketogroup reduction.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

New anti-cancer agent works without oxygen

Why tumors shrink but don’t disappear. “As tumors grow very quickly, consume a lot of oxygen and their vascular growth can’t necessarily keep pace, they often contain areas that are…

First blueprint of the human spliceosome revealed

Researchers detail the inner workings of the most complex and intricate molecular machine in human biology. Researchers at the Centre for Genomic Regulation (CRG) in Barcelona have created the first…

A paper-aluminum combo for strong, sustainable packaging

Takeout containers get your favorite noodles from the restaurant to your dining table (or couch) without incident, but they are nearly impossible to recycle if they are made from foil-lined…